Click here to receive MS news via e-mail
Find out more about new potential treatments for MS that are currently in phase 2 (mid-stage) or phase 3 (late-stage) clinical trials. These treatments aren’t available yet, but have reported promising results. Keep coming back to read about the latest updates and newest potential treatments.
It’s important that potential treatments for MS are tested in clinical trials to make sure that only safe and effective treatments reach people with MS. Clinical trials are usually completed in three phases before a treatment can be licensed.
Around one in ten potential treatments makes it through all three phases of clinical trials. This is because the treatments have to be tested in humans for the first time (phase 1), will need to meet strict safety and effectiveness criteria, and will have to be proven as effective in large numbers of people.Read more about the research process here.
There are currently 11 licensed treatments for people with relapsing remitting MS, along with several symptom management treatments for people with all types of MS.
Find out about the treatments that are currently in trials for:
Relapsing remitting MS
Phase 3
RPC1063
RPC1063 is an oral medication thought to prevent a subset of immune cellsfrom entering the brain and spinal cord.
Daclizumab
Daclizumab is an injectable drug that can reduce the number of immune cells present in the body
Ocrelizumab
Ocrelizumab is an intravenous infusion that targets cells of the immune system.
Ofatumumab
Ofatumumab is an injectable drug that can alter the behaviour of certain immune cells.
Laquinimod
Laquinimod is a tablet that is thought to stop immune cells reaching the brain.
Ponesimod
Ponesimod is an oral treatment that might stop immune cells reaching the brain.
Phase 2
Anti-LINGO-1
Anti-LINGO-1 is an intravenous infusion treatment that has been shown to have the potential to repair myelin.
Minocycline
Minocycline is an oral antibiotic currently used to treat bacterial infections and can prevent inflammation.
Raltegravir
Raltegravir is an oral antiretroviral drug that can fight viral infections.
Rituximab
Rituximab is an intravenous infusion that can reduce the number of immune cells in the body.
MT-1303
MT-1303 is an oral treatment that alters the behavior of immune cells.
Lipoic acid
Lipoic acid is an oral treatment that may prevent immune cells from reaching the brain.
Clemastine
Clemastine is an oral treatment that has been shown to suppress the immune system and may promote myelin repair.
ATL1102
ATL1102 is an injection that prevents immune cells from reaching the brain and spinal cord.
Vatelizumab
Vatelizumab is an infusion that prevents certain immune cells from building up at sites of inflammation in MS.
Progressive MS
Phase 3
Ocrelizumab
Ocrelizumab is an intravenous infusion that targets cells of the immune system.
MD1003
MD1003 is an oral medication that has shown the potential to promote myelin repair.
Masitinib
Masitinib is an oral treatment that blocks some of the body’s immune responses.
Siponimod
Siponimod is an oral treatment that stops immune cells from reaching the brain.
Fingolimod
Fingolimod is an oral treatment that stops certain immune cells from reaching the brain.
Phase 2
Phenytoin
Phenytoin is an oral treatment that has been shown to have the potential to protect nerve cells in the brain and spinal cord.
Anti-LINGO-1
Anti-LINGO-1 is an intravenous infusion treatment that has been shown to have the potential to repair myelin.
MS-SMART
MS-SMART is a trial involving three oral treatments – amiloride, fluoxetine and riluzole – that have been shown to have neuroprotective properties.
Rituximab
Rituximab is an intravenous infusion that can reduce the number of immune cells in the body.
Simvastatin
Simvastatin is an oral treatment that has been shown to have neuroprotective properties.
Lipoic acid
Lipoic acid is an oral treatment that may prevent immune cells from reaching the brain.
Dirucotide
Dirucotide is an intravenous infusion treatment believed to suppress the immune response against myelin.
Natalizumab
Also known as Tysabri, natalizumab prevents immune cells from leaving the blood stream and entering the brain and spinal cord.
Fluoxetine
Fluoxetine is a licenced medication in the treatment of depression. It is also currently being tested in a phase 2 clinical trial called MS-SMART in people with secondary progressive MS.
Riluzole
Riluzole is a licenced medication for motor neurone disease (MND). It is also currently being tested in a phase 2 clinical trial called MS-SMART in people with secondary progressive MS.
Amiloride
Amiloride is a licenced medication in the treatment of heart disease. It is also currently being tested in a phase 2 clinical trial called MS-SMART in people with secondary progressive MS.
Laquinimod
Laquinimod is a tablet that is thought to stop immune cells reaching the brain.
MIS416
MIS416 is an infusion that is thought to alter the behaviour of certain immune cells in MS.
MN-166
MN-166 is a tablet thought to have anti-inflammatory effects and to protect against cell death, which may be beneficial in reducing nerve cell loss in MS.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News
Provides educational information, resources and services for those affected by MS
We Believe YOU (the MS Patients and Caregivers) should Be Empowered with Multiple Sclerosis information
.===================================
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
